<DOC>
	<DOCNO>NCT03042572</DOCNO>
	<brief_summary>The primary objective trial investigate whether intramuscular administration allogeneic mesenchymal stromal cell ( MSC ) safe potentially effective , assess composite outcome mortality , limb status , clinical status ( Rutherford classification ) pain score ( visual analogue scale ) , patient no-option severe limb ischemia ( SLI ) . The investigator conduct double-blind , placebo-controlled randomized clinical trial investigate effect allogeneic bone marrow ( BM ) -derived MSC patient SLI , eligible conventional surgical endovascular therapy . The investigator intend include 60 patient , randomize undergo 30 intramuscular injection either BM-MSC ( 30 injection site 5*10^6 MSCs ) placebo lower leg ischemic extremity . Primary outcome i.e . therapy success , composite outcome consider mortality , limb status , clinical status ( Rutherford classification ) change pain score , assess six month .</brief_summary>
	<brief_title>Allogeneic Mesenchymal Stromal Cells Angiogenesis Neovascularization No-option Ischemic Limbs</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Age &gt; 18 year Severe Peripheral Artery Disease ( PAD ; Fontaine class III / IV ) : Fontaine III ( Rutherford 4 ) : persistent , recur rest pain require analgesia Fontaine IV ( Rutherford 5 ) : nonhealing ulcer present &gt; 4 week without evidence improvement response conventional therapy Ankle brachial index &lt; 0.6 unreliable ( noncompressible proportion Fontaine classification ) Not eligible surgical endovascular revascularization Written inform consent . History neoplasm malignancy past 10 year Serious know concomitant disease life expectancy le one year Rutherford 6 amputation short term ( within 12 week ) inevitable Pregnancy unwillingness use adequate contraception study Uncontrolled acute chronic infection systemic symptom Followup impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Critical Limb Ischemia ( CLI )</keyword>
	<keyword>Severe Limb Ischemia ( SLI )</keyword>
	<keyword>Peripheral Artery Disease ( PAD )</keyword>
	<keyword>Peripheral Artery Occlusive Disease ( PAOD )</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Mesenchymal stromal cell ( MSC )</keyword>
	<keyword>Mesenchymal stem cell ( MSC )</keyword>
</DOC>